Skip to main content

Barclays Remains a Buy on Cardinal Health (CAH)

Tipranks - Tipranks - Sat Feb 7, 3:30AM CST

Barclays analyst Glen Santangelo maintained a Buy rating on Cardinal Health today and set a price target of $243.00.

Claim 50% Off TipRanks Premium

Santangelo covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical, Idexx Laboratories, and Cencora. According to TipRanks, Santangelo has an average return of 6.1% and a 53.13% success rate on recommended stocks.

In addition to Barclays, Cardinal Health also received a Buy from TD Cowen’s Charles Rhyee in a report issued yesterday. However, on the same day, TipRanks – OpenAI reiterated a Hold rating on Cardinal Health (NYSE: CAH).

See Insiders’ Hot Stocks on TipRanks >>

Based on Cardinal Health’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $64.01 billion and a net profit of $450 million. In comparison, last year the company earned a revenue of $52.28 billion and had a net profit of $416 million

Read More on CAH:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).